Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Palo Alto Networks Inc (PANW) Price & Performance

Novo Nordisk A/STrade
Palo Alto Networks IncTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Palo Alto Networks Inc — how do they compare? Novo Nordisk A/S trades at $46.39 (market cap $207.85B), while Palo Alto Networks Inc trades at $387.15 (market cap $312.80B). The key difference: Palo Alto Networks Inc is the larger of the two by market cap, and Novo Nordisk A/S pays a 3.81% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.

NVOPANW
Market Cap
$207.85B$312.80B
Sector
HealthTechnology
52-Week High
$63.98$385.04
52-Week Low
$35.29$141.67
Enterprise Value
$222.55B$311.76B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Palo Alto Networks Inc

Palo Alto Networks (PANW) trades at $386.64, up 0.42% today, nearing its 52-week high with strong bullish technical signals. Recent earnings beats, including Q1 2026 EPS of $0.85 versus $0.793 expected, and robust revenue growth to $9.22B in 2025 highlight fundamental strength. Positive sentiment is driven by AI cybersecurity demand, as noted in recent news, though valuation ratios like P/E of 333.74 remain elevated.

Outlook is optimistic due to cybersecurity tailwinds and AI innovation, but risks include high valuation, integration costs from acquisitions, and regulatory scrutiny, such as China's cybersecurity review. Analyst consensus is strongly bullish with a $344.94 price target, suggesting potential downside from current levels amid growth execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.

Read more on PANW